Inhibition of cortico-amygdala projections underlies affective bias modification by psilocybin - Claydon MDB; Hinchcliffe JK; Bartlett J; Golden CT; Thomas CW; Gilmour G; Mellor JR; Bortolotto ZA; Robinson ESJ. (bioRxiv, 2026)

Serotonergic modulation of cortical gamma synchronization: right-lateralized psilocin effects on 40 Hz auditory steady-state responses in rats. - Griškova-Bulanova I; Vejmola Č; Páleníček T. (2026)

A Phase 2b Double-blind, Randomized, Low-dose Comparator-controlled Clinical Trial to Assess the Efficacy and Safety of NPX-5 in Psilocybin-assisted Psychotherapy for the Treatment of Adjustment Disorder Associated With Cancer. - Psyence Australia Pty Ltd (ClinicalTrials.gov, 2026)

Study of Psilocybin for Anorexia in Young Adults - Marissa Raymond-Flesch; MD; MPH (ClinicalTrials.gov, 2026)

Differential Effects of Acute and Chronic Fluoxetine on Psychedelic-Induced Behavior in Mice: Implications for Clinical Trials. - Wood BJ; Vest MF; Carfagno C; Bartley KR; Sharma P; Halberstadt AL; Blough BE; Murnane KS. (2026)

Synthesis and Characterization of Psilocybin Metabolites and Deuterated Analogs. - Williamson SE; Burkhartzmeyer EK; Faley MT; Ohana RF; Guzei IA; Valley M; Cali JJ; Sherwood AM. (2026)

Multidimensional Ego-Dissolution Assessment (MEDA): Scale Development and Substance-Specific Comparisons - Senānāyaka R. (PsyArXiv, 2026)

Effects of Psilocybin on Electrophysiology and the Dynamic Content of Thought - Johns Hopkins University (ClinicalTrials.gov, 2026)

Multidimensional Ego-Dissolution Assessment (MEDA): Scale Development and Substance-Specific Comparisons (PsyArXiv, 2026)

Psilocybin or Nicotine Patch for Smoking Cessation: A Pilot Randomized Clinical Trial. - Johnson MW; Naudé GP; Hendricks PS; Garcia-Romeu A. (2026)

Psilocybin Reshapes Anterior Cingulate Network Neuropathic Topology to Reduce Chronic Pain - Corder Greg; Rogers Sophie; Oswell Corinna (The Journal of Pain, 2026)

MedCheck: FDA Reviews NDA for Narcolepsy Drug, Green-Lights Psilocybin Trial for PTSD, and More - Richmond Linda M. (Psychiatric News, 2026)

Journeying into Right Relations: Scientists Turn to Psilocybin to Shift Psychological Burdens of Global Environmental Change and Find Transformational Pathways Forward - Wrathall David J.; Gosnell Hannah; Wickson Fern; Spanger Erika; Associates* (Action Research, 2026)

Meaning and Psychedelics in Palliative Care: A Narrative Review. - Alexander WB; Hansen ED; Anderson BT; Zarrabi AJ; Rogers AH; Loewen G; Ficarro ZR; Alexander MH; Schaefer D; Case AA (Journal of pain and symptom management, 2026)

Psilocybin shapes neural plasticity in selective brain networks. - Lewis S. (2026)

Psilocybin and Ibogaine in Cocaine-Seeking: Extinction Enhancement Without Relapse Prevention. - Koutrouli IRA; Brejtr V; Schwendt M; Witek K; Charalambous C; Aleksič K; Miniariková N; Lhotková E; Toman M; Nikolič M; Jurok R; Cihlářová P; et al. (2026)

[Perspectives opened up by the physiopathological understanding of psychiatric disorders]. - Girault N; Quiroga L; Jedrecy S; Bertin S; Djonouma N; Fossati P. (2026)

Psychedelics, Eleusis, and the Invention of Religious Experience. - Mosurinjohn S; Ascough R (Psychedelic medicine (New Rochelle, N.Y.), 2026)

Psychedelics and the Extracellular Matrix: Rewiring Neuroplasticity and Metaplasticity for Next-Generation Psychiatric Therapies. - Zhang J; Lin C; Lv X; Zhao H; Wang X. (2026)

Psilocybin-assisted therapy for demoralisation in hospice patients: feasibility, safety and preliminary efficacy. - Beaussant Y; Sager Z; Brennan C; Kristan I; Ljuslin M; Mazzola E; Macdonald D; Murphy ME; Nigam K; Rinaldi AD; Sanders J; Schaefer KG; et al. (2026)

Psychedelic therapy and cultural humility. - Gearin A; Docherty J; Sun X; Cheung EH; Tanuseputro P. (2026)

Calcium activation mechanism of a noncanonical aromatic L-amino acid decarboxylase from psilocybin mushroom Psilocybe cubensis. - Li T; Reynolds EE; Wang Z; Torrens-Spence MP; Weng JK; Wang Y. (2026)

Pharmacological regulation of adult brain neuroplasticity: Synergistic roles of neuropeptide signaling, psychedelics, and synaptic modulators. - Shokr MM; Fawzy MN; Abdelaziz AM. (2026)

Psilocybin for psychiatric disorders: History, clinical trials, neuroimaging, and regulations. - Yonezawa K; Hirata M; Takano H; Kusudo K; Tomiyama S; Harada L; Suzuki K; Nutt DJ; Uchida H; Tani H. (2026)

Does Psilocybin Change Synaptic Density in the Brains of Patients With Amnestic Mild Cognitive Impairment - Centre for Addiction; Mental Health (ClinicalTrials.gov, 2026)

The Effects of Psilocybin in Healthy Volunteers: Psychological, Biochemical and Electrophysiological Biomarkers. - Gabriella Gobbi (ClinicalTrials.gov, 2026)

Pilot study of psilocybin in patients with post-treatment lyme disease. - Garcia-Romeu A; Naudé GP; Rebman AW; So S; Yaffe A; Geithner I; Kozero EA; Yang T; Soloski MJ; Aucott JN. (2026)

Advancing cancer neuroscience through stress modulation: Interdisciplinary potential of psilocybin and ketamine. - Courtes AC; Myers B; Daly N; Jones G; Soares JC; Zarate CA; Machado-Vieira R. (2026)

SSRIs, Psilocybin, MDMA, and Disease Modeling: Strategies to Advance PTSD Treatment - Ishii M; Zervas M. (ScienceOpen Preprints, 2026)

Efficacy and Safety of Psychoactive Tryptamines in Addiction: A Systematic Review. - van der Meer PB; Schukking N; Dik M; van Reemst A; Fuentes JJ; Kaptein AA; Schoones JW; Verboeket S; de Waal MM; Goudriaan AE; Kramers C; Schellekens A; et al. (2026)

Inpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder: a Randomized Double-blind Trial - Johns Hopkins University (ClinicalTrials.gov, 2026)

Safety for Home Administration of Microdose Psilocybin Use - Johns Hopkins University (ClinicalTrials.gov, 2026)

Investigation of Psychedelic Effects in Psychoactive Substances - Johns Hopkins University (ClinicalTrials.gov, 2026)

Delayed psilocybin treatment after repeated mild traumatic brain injury recovers chronic behavioural deficits, reduces microglial density, and enhances hippocampal neurogenesis in rats - Shultz S; Allen J; O'Regan G; Brand J; Liknaitzky P; O'Brien T; Christie B; McDonald S. (Research Square, 2026)

Safety and Efficacy of Microdosing Psilocybin over 8 Weeks for Major Depressive Disorder: A Randomized Clinical Trial - Petranker R; Farb N; Syed O; Li E; Shore D; Anderson T; Blackman A. (Research Square, 2026)

Psychedelic medicine: mechanisms, evidence, and translation to practice. - Jacobs E; Zahid Z; Hinkle J; Nayak S; Yaden DB. (2026)

Trends in first-time psychedelic and other hallucinogen use in the United States: Results from the National Survey on Drug Use and Health. - Montoy JCC; Wang RC; Coker AR; Anderson BT. (2026)

Ethical Complexities and Best Practices in Informed Consent for Psychedelic Services: A Qualitative Study on Expert Perspectives - Chwyl C; Bazinet A; Wilson-Poe A; Hoffman K; Pertl K; McCrimmon S; Korthuis P; Luoma JB. (PsyArXiv, 2026)

Ethical Complexities and Best Practices in Informed Consent for Psychedelic Services: A Qualitative Study on Expert Perspectives (PsyArXiv, 2026)

Effects of Psilocybin and Select Pharmaceutical Interactions - McDowell Jordan; Middleton Jada; Bluett Alanna; Kozachenko Alisa; Attar Bayan; Saini Yuvraj; Burke Jennifer; McPhee Cayden; Mutahera Mutahera; Ahmed Talya; Ibrahim Nabila; Atukwatsibwe Gilbert; et al. (MacEwan University Student eJournal, 2026)

Regulatory ambiguity and governance challenges for psilocybin mushrooms in Brazil. - Nogueira M; García-Hernández S; Roberto GS; Rodrigues DC. (2026)

Sex-dependent developmental changes in behavior, brain structure, functional connectivity, and sensory perception following exposure to psilocybin during adolescence. - Sahoo I; Masadi S; Maheswari A; Utama R; Abeer MI; Soltanpour S; Nasseef MT; Chukwuemeka T; Sinhal N; Pandit J; Ortiz RJ; Cavallaro N; et al. (2026)

Mindfulness-Based Psilocybin-Assisted Therapy (MB-PAT) for cancer-related demoralization in Canada: the case for a hybrid group-based delivery model - Albertyn CP; Richard J; Shore RJ; Carlson LE. (PsyArXiv, 2026)

Pilot Study of Psilocybin-Assisted Therapy for Demoralization in Patients Receiving Hospice Care - PATH Study - Yvan Beaussant; MD; MSci (ClinicalTrials.gov, 2026)

Mindfulness-Based Psilocybin-Assisted Therapy (MB-PAT) for cancer-related demoralization in Canada: the case for a hybrid group-based delivery model (PsyArXiv, 2026)

Sense-Making Around Psilocybin in UK Women Experiencing Cancer-Related Existential Distress: An Interpretative Phenomenological Analysis. - Khan Z; Weaver S; Dando RV; Schlag AK; Neill JC; Wainwright V. (2026)

Rebuttal to "Questioning the recovery of dissociated traumatic memories under psilocybin". - Knatz Peck S; Brewerton TD. (2026)

Microdosing psilocybin for major depressive disorder: study protocol for a phase II double-blind placebo-controlled randomised partial crossover trial. - Beidas Z; Ragnhildstveit A; Blackman A; Anderson T; Fewster E; Syed OA; Sobolenko V; Kanca IK; Jaglinska M; Son T; Farb N; Petranker R. (2026)

Management of obsessive-compulsive disorder in adults. - Abramowitz JS; Abramovitch A; McKay D; Draffin A. (2026)

Effects of LSD, DMT and psilocybin on cognitive and psychological functions: A systematic review of the literature. - Kase M; Kaup KK; Aru J. (2026)

Hallucinogenic Therapy in Alzheimer's Disease targeting Mitochondria-Associated Membranes. - Minauro-Sanmiguel F; Vargas-Perez H. (2026)

Psilocybin-assisted cognitive behavioral therapy for major depressive disorder: A pilot trial. - Weintraub MJ; Jeffrey JK; Ichinose MC; Bergman RL; Shapiro B; Barnett G; Artin H; Lynn M; Salimian A; Grody S; Ramesh R; Eales L; et al. (2026)

Hope for Neurotic Disorders: A Summary of New Zealand Research on the Development of Biomarkers and Novel Treatments. - McNaughton N; Shadli SM; Beaglehole B; Glue P. (2026)

Electrophysiological effects of psilocybin co-administered with midazolam. - Sutherland MH; Nicholas CR; Lennertz RC; Wenthur CJ; Krause BM; Sauder CJ; Riedner BA; Smith RF; Hutson PR; Raison CL; Banks MI. (2026)

Network pharmacology and molecular simulation reveal the entourage effect mechanisms of psilocybin-producing mushrooms on the brain. - Murray Z; Lewies A; Wentzel JF; Schutte-Smith M; Erasmus E; Noreljaleel A; Visser H; Wilhelm A; Issahaku AR. (2026)

Ischemia-Induced Neurodegeneration in Glaucoma: Mechanistic Insights and Translational Opportunities for Psychoplastogen-Based Therapies. - Dolenec P; Pelčić G; Pilipović K; Mršić-Pelčić J; Hrkać AH. (2026)

A Phase 1 Translational Study to Assess Brain Activity Using Functional Magnetic Resonance Imaging (fMRI) and to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of MLS101 (Psilocybin) in Healthy Volunteers - MycoMedica Life Sciences PBC (ClinicalTrials.gov, 2026)

Psychedelic Healing: Adjunct Therapy Harnessing Opened Malleability - Johns Hopkins University (ClinicalTrials.gov, 2026)

Trip sitting or just sitting? Session facilitators substantially influence psychedelic experiences in clinical trials but not in healthy ones. - Goldy SP; Sepeda ND; Hilbert SN; Bari BA; Garcia-Romeu A; Gukasyan N; Barrett FS; Yaden DB; Nayak SM. (2026)

Single Dose Psilocybin for a Post-surgical Trauma Inpatient Population for Pain, Mood, and Opioid Use Disorder - Trent Emerick (ClinicalTrials.gov, 2026)

Psilocybin-assisted Therapy for Comorbid Major Depressive Disorder and Alcohol Use Disorder: A Pilot Randomized Clinical Trial - Centre for Addiction; Mental Health (ClinicalTrials.gov, 2026)

Low-income group psilocybin assisted therapy for depression: An Oregon feasibility study - Hicks Matthew; Hicks Olivia; Bradley Ryan; Zwickey Heather (Journal of Psychedelic Studies, 2026)

Time-Dependent Effects of Rapid-Acting Antidepressants in iPSC-Derived Neurons from Treatment-Resistant Depression and Healthy Volunteers - Johnston J; Jones G; Peng S; Yuan P; Yavi M; Kadriu B; Henter I; Quintanilla B; Elkahloun AG; Moaddel R; Schulmann A; Akula N; et al. (Research Square, 2026)

Therapeutic effects of psilocybin in major depressive disorder: a systematic review and meta-analysis exploring dose effects. - He Z; Wang Y; Chen J; Cheng J; Feng Y; Niu S; Yan J. (2026)

Examining the effects of psilocybin-assisted psychotherapy on anhedonia in treatment-resistant depression. - Kaczmarek ES; Rodrigues NB; Chisamore N; Doyle Z; Meshkat S; Blainey MG; Brudner R; Ali S; Teopiz KM; McIntyre RS; Rosenblat JD. (2026)

Mystical but Not Challenging Experiences Predict Symptom Improvement After Psilocybin for Treatment-Resistant OCD - Shnayder S; Agin-Liebes G; Hubert T; Ching THW; Hokanson J; Pittenger C; Kelmendi B; Adams T. (PsyArXiv, 2026)

Mystical but Not Challenging Experiences Predict Symptom Improvement After Psilocybin for Treatment-Resistant OCD (PsyArXiv, 2026)

The potential of event-related beta oscillations as biomarkers for neuromodulatory treatment efficacy. - Habelt B. (2026)

Psychedelics in functional disorders: A scoping review. - Bhagavan C; Carter O; Bryson A; Dandash O; Kanaan R. (2026)

Safety and Psychological Effects of Psilocybin and D-Serine Formulation in Healthy Volunteers - Hadassah Medical Organization (ClinicalTrials.gov, 2026)

A Phase 2a, Open-label, Pilot Study to Assess the Safety and Efficacy of Oral Psilocybin (TRP-8802) Administration in Concert With Psychotherapy Among Adult Patients With Irritable Bowel Syndrome: A Randomized Delayed Treatment Control Design - TRYP Therapeutics (ClinicalTrials.gov, 2026)

Psilocybin AsSisted pSychotherapy for the treatmENt of Gambling disordER: a Pilot Study - Nantes University Hospital (ClinicalTrials.gov, 2026)

India's Unique Legal Framework for Psilocybin Mushroom Research: An Unprecedented Opportunity in Psychiatric Therapeutics. - Tom A; Reddy BSC; Sethi MIS; Math SB. (2026)

Cardiac Consequences Associated with Psychedelic Use: A Systematic Review of Lysergic Acid Diethylamide, 3,4-Methylenedioxymethamphetamine, and 5-Hydroxytryptamine 2B-Mediated Valvular Heart Disease. - Xu T; Wong S; Le GH; Dri CE; Teopiz KM; Lu A; Lee S; Rhee TG; Yin L; Bargiota S; Ho R; McIntyre RS. (2026)

Challenges with clinical trial participants in studies with classical psychedelics: A position statement from the National Network of Depression Centers' task group on psychedelics and related compounds. - Lewis BR; Reid MJ; Novick AM; Byrne K; Niciu MJ; Fonzo GA; Meyer TD; Feifel D; El-Mallakh RS; Soares J; Suppes T; Barrett FS. (2026)

Retraction: Acute psilocybin increased cortical activities in rats. - Frontiers Editorial Office. (2026)

Acute psilocin increased cortical activity in rat. - Liu J; Wang Y; Xia K; Wu J; Zheng D; Cai A; Yan H; Su R. (2026)

Psilocybin exerts differential effects on social behavior and inflammation in mice in contexts of activity-based anorexia - Shadani Sheida; Greaves Erika; Andrews Zane B.; Foldi Claire J. (Psychedelics, 2026)

Computational Analysis of Psilocybin Effects on Three-Choice Touchscreen Reversal Learning in Rats: A Pilot Study - Gregersen Anton T.; Whelan Tobias; Golden Caroline; Blackmore Thomas; Palner Mikael (Psychedelic Medicine, 2026)

MDMA and Psilocybin Regulate Oligodendrocyte-Lineage Cell Numbers and Anxiety-Like Behaviors in a Rat Model of Fear. - Bostancıklıoğlu M; Kaplan DS; Bal R; Yiğit E; Ulusal H; Temiz E. (2026)

Spatiotemporal mapping of brain organisation following the administration of 2C-B and psilocybin. - Mallaroni P; Singleton SP; Mason NL; Satterthwaite TD; Ramaekers JG. (2026)

Can LLMs Get High? A Dual-Metric Framework for Evaluating Psychedelic Simulation and Safety in Large Language Models - Ben-Zion Z; Simon G; Lazebnik T. (Research Square, 2026)

Real-world effectiveness and safety of psychedelic-assisted psychotherapy: Outcomes from a large-scale compassionate use cohort in Switzerland. - Aboulafia-Brakha T; Buchard A; Mabilais C; Alaux S; Amberger C; Furtado L; Seragnoli F; Briefer JF; Thorens G; Sabé M; Szczesniak L; Iuga R; et al. (2026)

Psilocybin wirkt bei therapieresistenter Depression - Müller Thomas (DNP - Die Neurologie & Psychiatrie, 2026)

Ketamine and psilocybin for athletes: A therapeutic breakthrough or a slippery slope? - Zandonai Thomas; Venturini Sofia; Corazza Ornella (Performance Enhancement & Health, 2026)

Attitudes and perceptions of Portuguese mental health professionals on the therapeutic use of psilocybin and methylenedioxymethamphetamine (MDMA). - Encantado Jorge; Carvalho Laura C.; Mota Pedro; Cunha Catarina; Garcia-Romeu Albert; Johnson Matthew W.; Teixeira Pedro J. (Professional Psychology: Research and Practice, 2026)

Ketamine, Psychedelics, and Psychotherapy: Reframing, Redefining, Renaming Treatment Models. - Swainson J; Brietzke E; Khullar A; McIntyre RS; Soares CN (Canadian journal of psychiatry. Revue canadienne de psychiatrie, 2026)

Placebo Effects in the Treatment of Depression-Implications for the Psychedelic Renaissance. - Ansari M; Elliott SI; Holmes SE; Sanacora G (Neurologic clinics, 2026)

Difficulties following naturalistic psychedelic use and associations with adverse childhood experiences. - Olofsson M; Osika W; Goldberg SB; Hendricks PS; Petrovic P; White T; Stenfors CUD; Chaturvedi S; Simonsson O (The International journal on drug policy, 2026)

Participant Experiences of Therapeutic Touch in Psilocybin-Assisted Therapy. - Ham R; Gardner J; Carter A; Liknaitzky P. (2026)

Psychedelic- and Substance-Assisted Therapies in Global Mental Health: Bridging Cultures, Evidence, and Access. - Halm S. (2026)

We Licked the Toads so You Don't Have to: A Comprehensive Analysis of the Chemical Syntheses of the Classical Psychedelics Bufotenin(e) and 5-Methoxy-N,N-Dimethyltryptamine. - Homon A; Laramie J; Hayward JJ; Trant JF (ChemMedChem, 2026)

[Pharmacological post-acute treatment of alcohol use disorder: Established strategies and innovative approaches]. - Roser P. (2026)

Bioactive compounds from Psilocybe cubensis mycelial cultures with transient anxiolytic effects in mice. - Kala K; Bederska-Lojewska D; Lazur J; Gasior K; Maslanka A; Szewczyk A; Sulkowska-Ziaja K; Turek J; Szewczyk B; Pilc A; Muszynska B. (2026)

Psilocybin-Induced Neuroplasticity and Sustained Antidepressant Effects - Komarczewska Anna Maria; Matusiak Filip; Brzoza Klaudia; Kociński Michał; Iglewski Patryk; Pietrasz Michał (Quality in Sport, 2026)

Single-dose psilocybin promotes cell-type-specific changes of neurons in the orbitofrontal cortex. - Huang Z; Wei X; Wang Y; Tian J; Dong J; Liang B; Lu L; Zhang W. (2026)

Regarding "The molecular mechanisms through which psilocybin prevents suicide: evidence from network pharmacology and molecular docking analyses". - Kristensen J. (2026)

The Use of Psilocybin in the Treatment of Depressive Disorders: A Narrative Review. - Siwek L; Nowocien M; Balajewicz B; Samborska A; Szukalska S; Karczewska M; Lichwala K; Wróblewski K; Wróblewska P. (2026)

Indigenous Knowledge Systems & Psychedelic Science: Towards Ethical and Reciprocal Collaboration. - Magar V; Robbins M; Fernández Lobo Blanco ÓML; Ali IL; Anderson B; Grob C; Henningfield JE; Kryskow P; Kuiper H; Loizaga-Velder A; Rush B; Volat M; et al. (2026)

PSilocybin for psYCHological and existential distress in PALliative care (PSYCHED-PAL): A single arm unblinded clinical trial. - Downar J; Lapenskie J; Anderson K; Parsons G; Polskaia N; Lalumiere G; Lawlor P. (2026)

Improving access to psilocybin-assisted therapy: barriers, challenges, and recommendations. - Tsang VWL; Roney C; Kryskow P; Dames S. (2026)

Psilocybin and the Evolutionary Significance of Altered Neural States: Interaction-Based Perspectives Beyond Deterrence Models - Rebensburg P. (EcoEvoRxiv, 2026)

PSILOCYBIN IN PSYCHIATRIC PRACTICE AND PSYCHEDELIC-ASSISTED THERAPY FOR TREATMENT-RESISTANT DEPRESSION - Łukasz Deska; Cezary Kosmecki; Dawid Głaz; Natalia Kamińska; Wojciech Sołtys; Magdalena Stolarczyk; Maksymilian Głaz; Mateusz Stronczyński; Aleksandra Jagura-Sukiennik; Julia Wawerska (International Journal of Innovative Technologies in Social Science, 2026)

High hopes? Precision psychedelic addiction medicine. - Zafar RR; Kleine P; Kurtin D; Wall M; Erritzoe D. (2026)

PSilocybin Microdose for psYCHological and Existential Distress in PALliative Care (PSYCHED-PAL): A Multi-site Phase 3 Double-blind, Placebo-controlled, Parallel-arm Clinical Trial - Bruyère Health Research Institute. (ClinicalTrials.gov, 2026)

Group Retreat Psilocybin Therapy for People with Metastatic Cancer with Anxiety and Depression: A Rite of Passage Facilitation Model for a Phase 1/2 Study - Back Anthony L.; McGregor Bonnie A.; Billingsley Lindsay; Blom Dianna; Callan George; Myers Susanna; Guy John; Kumar Sameet; Layer Melissa; Levin Jackie; Perez Juliana; Thompson Peter; et al. (Psychedelic Medicine, 2026)

A Promise Without Panacea: Psychedelic-Assisted Therapies in Modern Psychiatry. - Raza M; Kaur J. (2026)

Psilocybin-induced alterations in EEG power, connectivity and network dynamics in healthy subjects: Correlations with subjective experience and implications for therapeutic applications. - Ip CT; Olbrich S; de Bardeci M; Monn A; Ort A; Smallridge JW; Vollenweider F. (2026)

Design, Synthesis, and Pharmacokinetic Profiling of Fluorinated Reversible N-Alkyl Carbamate Derivatives of Psilocin for Sub-Hallucinogenic Brain Exposure. - Banzato M; Colognesi M; Lucatello L; Comai S; Pasut G; Capolongo F; Orian L; Biasutto L; Signor A; Gabbia D; Manfredi PL; De Martin S; et al. (2026)

Self-medication with psychedelics: a scoping review and narrative synthesis of review-level evidence. - Shiju S; Tirumala R; Marseille E. (2026)

Effects of psilocybin on personality, psychiatric symptoms, and values: Exploring mediating effects of the acute psychedelic experience. - Kerr-Gaffney J; Myrtle S; Askari F; Bird C; Modlin NL; Young AH; Rucker J. (2026)

The Evaluation of the Efficacy and Safety of the Use of Psilocybin in the Treatment of Adults with Treatment-Resistant Depression - Scott Rishika; Smith James (Emerging Minds Journal for Student Research, 2026)

Methodological moderators of psilocybin-assisted therapy in depression: A systematic review and meta-analysis. - Syed OA; Tsang B; Nestor SM; Lipsman N; Husain MI; Alam F; Giacobbe P. (2026)

A Phase 2 Trial of Psilocybin as an Adjunctive Treatment for OUD Patients Who Continue to Use Illicit Opioids Despite Adherence to Methadone Treatment - NYU Langone Health (ClinicalTrials.gov, 2026)

THE PSYCHEDELIC RENAISSANCE: A SYSTEMATIC REVIEW OF PSILOCYBIN AND LSD IN THE TREATMENT OF PSYCHIATRIC DISORDERS - Jakub Klepacz; Radosław Swędrak; Marzena Swojnóg; Zuzanna Dobrakowska (International Journal of Innovative Technologies in Social Science, 2026)

Consistency of protocol and safety data reporting in clinical trial registrations and corresponding publications of interventions involving MDMA and psilocybin. - Žuljević MF; Mijatović A; Orhanović R; Goasdoué G; Gujinović D. (2026)

The STARLIGHT Protocol: State-Funded Trial Assessing Recovery and Long-Term Impact of Guided Psilocybin for Healing Trauma - Baylor College of Medicine (ClinicalTrials.gov, 2026)

No evidence of immediate or persistent analgesic effect from a single dose of psilocybin in three mouse models of pain. - Gregory NS; Girard TE; Ram A; Casey AB; Malenka RC; Tawfik VL; Heifets BD. (2026)

Mushroom-Derived Carbon Nanosheets for Efficient Photothermal De-Icing Applications. - Prusti SP; Salian R; Das AK; Kumbhakar P. (2026)

Mindset over molecule: comparing self-transcendent and mystical experiences across recreational psilocybin, MDMA, and cannabis use. - Chwyl C; Spata A; Lucas W; Luoma JB. (2026)

Patient perspectives on research gaps in cluster headache. - Haghdoost F; Bahceci D; Delcourt C; Wijeratne T; Jensen RH; Cincinnato C; Tomlinson S; Wold B; Polito V; Carcel C; Ashraf U; Jenkins B; et al. (2026)

Psilocin mediates long-term synaptic depression in the prelimbic cortex through 5-HT2A receptor-independent mechanisms. - Domi A; Lucente E; Cadeddu D; Bengtsson N; Smedler E; Adermark L. (2026)

Effects of psilocybin and chronic mild stress on microglial activation in rat spinal cord: an ex vivo analysis. - Olejnik P; Kamińska K; Gołembiowska K; Kasarełło K. (2026)

Insights into psilocybin use among people with bipolar disorder: A thematic analysis of Reddit posts. - Mills L; Rossell SL; Carruthers SP. (2026)

﻿Systematic study of Panaeolus (Agaricales, Galeropsidaceae) sensu lato and psilocybin-producing traits of species from China. - He MQ; Yang WQ; Phurbu D; Liu F; Li JX; Cao B; Zhao RL. (2026)

Early response to psilocybin in adults with treatment-resistant depression as a predictor for antidepressant efficacy. - Doyle Z; Chisamore N; Kaczmarek ES; Johnson DE; Brudner RM; Weiglein G; Blainey MG; Bawks J; Riva-Cambrin J; Sethi R; McIntyre RS; Rosenblat JD. (2026)

Insights from the psychedelic experience integration session: Verbatims differentiate 3-month abstinence in alcohol use disorder with depressive symptoms. - Garcia Garcia M; Belahda D; Graux C; Serrand C; Igounenc N; Sergent F; Mura T; Luquiens A. (2026)

Group Retreat Psilocybin Therapy for People with Metastatic Cancer with Symptoms of Anxiety and Depression: Safety and Efficacy Outcomes of a Phase 1/2 Study - Back Anthony L.; McGregor Bonnie A.; Thorn Leslie L.; Baker Kelsey; Gooley Ted; Kaelen Mendel; Harvey Kalin; Guy John M.; Myers Susanna; Perez Juliana; Thompson Peter; Billingsley Lindsay; et al. (Psychedelic Medicine, 2026)

Safety and Efficacy of Monoamine Oxidase Inhibitors in Patients Who Use Psychoactive Substances: Potential Drug Interactions and Substance Use Disorder Treatment Data. - Rached G; Campana A; Fiani D; Nguyen C; Van den Eynde V; Gillman PK; Barnett BS. (2026)

Bridging the reporting gap: Application of the ReSPCT guidelines in psilocybin clinical trial protocols. - Swieczkowski D; Kwaśny A; Sadko K; Cubała WJ. (2026)

Aquahenosis: A non-pharmacological altered state of consciousness induced by Floatation-REST - Tobel T; Cone A; Choquette E; Garland M; Johnson M; Mink K; Lynch C; Frohlich J; Feinstein J; Reggente N; Khalsa SS. (PsyArXiv, 2026)

Psilocybin for Treatment-Resistant OCD: A Randomized Controlled Trial - Kelmendi B; Adams T; Ching THW; Grazioplene R; Kichuk S; Fram G; Patel P; Eilbott J; D’Amico E; Shnayder S; Martins B; Bohner C; et al. (PsyArXiv, 2026)

Aquahenosis: A non-pharmacological altered state of consciousness induced by Floatation-REST (PsyArXiv, 2026)

Psilocybin rapidly, but not immediately, reverses reward learning deficits in a durable manner in an inflammatory rat model of depressive symptoms - Hinchcliffe JK; Thomas CW; Gilmour G; Robinson ES. (bioRxiv, 2026)

Psilocybin for Treatment-Resistant OCD: A Randomized Controlled Trial (PsyArXiv, 2026)

Contextualizing Violence Risk Associated With Hallucinogens. - Durns T; Iannuzzi G. (2026)

The Psychological Support Model in Psilocybin Research: Psychotherapy in Disguise? - Jacobsen CF; Stenbæk DS; Poulsen S; Armand S. (2026)

A Phase III, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With Treatment-resistant Depression - COMPASS Pathways (ClinicalTrials.gov, 2026)

Effects of Psilocybin in Patients With Amyotrophic Lateral Sclerosis - Johns Hopkins University (ClinicalTrials.gov, 2026)

Chemical Design and Pharmacokinetics Enable Precision Psychedelic Therapeutics. - Renner AC; Kargbo RB. (2026)

Behavioral and Neural Mechanisms Supporting Psilocybin-assisted Therapy for Phantom Limb Pain - University of California; San Diego (ClinicalTrials.gov, 2026)

Self-administered complementary and alternative methods of treating mental disorders among students in Wrocław: a cross-sectional study. - Sobieraj J; Sleziak J; Szyszka M; Błażejewska M; Łukańko K; Soczomska P; Bodziony K; Piotrowski P. (2026)

Psilocin fosters neuroplasticity in iPSC-derived human cortical neurons - Koch P; Schmidt M; Hoffrichter A; Davoudi M; Horschitz S; Lau T; Meinhardt M; Spanagel R; Ladewig J; Köhr G. (Research Square, 2026)

Presence of 4-Hydroxy-N-methyl-N-ethyltryptamine in Commercially Available Products. - Barovic A; Pittiglio MK; Barrett JM; Aretz CDJ; Tesfatsion TT; Ramirez GA; Cruces W. (2026)

Psychedelic Modulation of Excitation/Inhibition Balance: A Dual-Phase Neurodevelopmental Model. - Kandilakis CL; Papatheodoropoulos C. (2026)

An exploration of the relationships between the effects of psilocybin on behavior, 5-HT2A receptor occupancy, and neuroplastic effects in mice. - Maltby CJ; Klein AK; Paschen E; Pinto J; Dvorak D; Hedde JR; Hanks AN; Bianchi M; Hughes ZA. (2026)

Associations of Couples' Psychedelic Use with Shared Reality and Relational Well-Being. - Cornelius T; Barba T. (2026)

Psychoactive mushroom edibles: trends and toxicities reported to the United States National Poison Data System®, 2023-2024. - Jorgenson DM; Santos Leon E; Vakkalanka JP; Krispin S; Radke JB. (2026)

The effect of psilocin on neurotransmitters release in the claustrum and on rat behavior. - Kościuk Z; Szpręgiel I; Bysiek A; Gołembiowska K. (2026)

Psilocybin and Bipolar Depression: Promise and Prudence. - Marques MG; Patarroyo-Rodriguez L; Singh B. (2026)

An open-label pilot study of psilocybin-assisted therapy for binge eating disorder. - Dallery J; Miller JL; Boissoneault J; Harvey L; Ives L; Knerr A; Blaes S; Ransom MN; Munson M; Gilligan JP; Silverman MH; Guzzo PR; et al. (2026)

The one that abstained: Psilocybe fuscofulva genome suggests two recent origins of the psilocybin gene cluster in Psilocybe - Slot J; Bradshaw A; Dentinger B; Borovička J; Konkel Z; Rockefeller A; Bollinger I. (bioRxiv, 2026)

Daily Administration of Psilocin Mucate (L-130) Produces a Favorable Safety Profile and Anxiolytic Effects in Rodents Exposed to Chronic Unpredictable Mild Stress. - Sancilio FD; Dariani M; Chavda P; Rajagopal HM; Tomlinson L. (2026)

The effects of psilocybin on psychological distress in cancer patients: a systematic review and meta-analysis. - Moshfeghinia R; Mostafavi S; Jazi K; Ghasemi AR; Khosravaninezhad Y; Narayanan S; Ahmadi J; Pasalar M. (2026)

Reported Safety Practices of Publicly Advertised Psychedelic Retreats. - McGuire AL; Neitzke-Spruill L; Robinson JO; Beit CS; Singh N; Mathai DS; Averill LA. (2026)

Psychological Therapy Quantity and Depressive Symptom Reduction in Psychedelic-Assisted Therapy: A Systematic Review and Meta-Analysis. - Florineth GA; Klima I; Boeker AL; Catzeflis P; Wopfner A; Denier N; Bracht T; Adorjan K; Pfammatter M; Müller F; Soravia LM. (2026)

Snapshot IP1 Detection Following 5-HT2A Receptor Stimulation in the Mouse Brain. - de la Fuente Revenga M; González-Maeso J. (2026)

Preclinical evaluation of psilocybin as an anti-inflammatory agent - Martínez-Álvarez N.; Erkizia-Santamaría I.; Tomás-Alvarado A.; Erdozain A.M.; Meana J.J.; Ortega J.E. (Neuroscience Applied, 2025)

Psilocybin increases connectivity between unimodal and transmodal networks in healthy volunteers listening to music - Benes M.; Gregus D.; Adamek P.; Palenicek T.; Horacek J. (Neuroscience Applied, 2025)

Psilocibina en cuidados paliativos: revisión sistemática de los efectos a nivel emocional y espiritual-existenciales - Toalombo-Eugenio Graciela Estefanía; Carrillo-Zavala Katheryne Viviana; Mayorga-Núñez Verónica Giovanna (Revista Metropolitana de Ciencias Aplicadas, 2025)

Effects of low-dose psilocybin on EEG markers of sensory processing in autistic and non-autistic adults - Ollari O.; Whelan T.P.; Ellis C.L.; Khalil N.; Moruzzi F.; Murphy D.G.M.; Daly E.; Mason L.; Puts N.; McAlonan G.M. (Neuroscience Applied, 2025)

Mismatch between psilocybin-induced head-twitch behaviour and psilocin brain levels in mice - Sellitti F.; Weber C.; Tamura É.; Li Z.; Thomann J.; Luethi D.; Simmler L.D. (Neuroscience Applied, 2025)

Preliminary results from an ongoing naturalistic survey study investigating dose-finding practices and effects of self-administered small amounts of psilocybin - Totomanova I.; Haijen E.C.H.M.; Hurks P.P.M.; Mason N.L.; Kuypers K.P.C. (Neuroscience Applied, 2025)

Temporal effects of a single oral dose of psilocybin on plasma circulating miRNAs in humans - O'shea A.; Ramaekers J.G.; Schreiber R.; Briedé J.J.; Krauskopf J.; Mason N.; Verheijen M.C.T. (Neuroscience Applied, 2025)

Behavioral and neuronal effects of psilocybin in mice - Weber C.; Sellitti F.; Ziming L.; von Arx J.; Simmler L.D. (Neuroscience Applied, 2025)

Psilocybin: clinical potential, mechanistic insights, and biotechnological advances for scalable production - Islas-Vargas J; Armenta S; Rivera-Román ÁA; Hernández-León S; Méndez-Hernández JE; Arce-Cervantes O. (2025)

Toxicology and Pharmacological Interactions of Classic Psychedelics. - Thomas K. (2025)

Pharmacological Properties of Psychedelics with a Special Focus on Potential Harms. - Holze F; Liechti ME; Müller F. (2025)

Anxiety and Affective Symptoms Related to the Use of Classic Psychedelics: A Systematic Review. - Viljoen G; Betzler F (Current topics in behavioral neurosciences, 2025)

Informed Consent in Psychedelic-Assisted Therapy. - Bradberry MM; Appelbaum PS; Gukasyan N. (2025)

Development of Psilocybe Mushroom Species Reference Material-Cultivation Parameters and Chemical Profiles. - Windsor C; Kreynes AE; Chilton JS; Chioffi WA; Niebergall C; Dodds K. (2025)

Toward Standardized Products Containing Biomass of Psilocybe Cubensis Fungi. - Foster K; Morrison I; Daniel S; Antoine J; Thankappan B; De La Haye W; Tyler M; Grant C; Delgoda R. (2025)

Building standards of psychedelic care: Qualitative examination of expert perspectives on safety, inclusion, and accountability. - Chwyl C; Wilson-Poe AR; Hoffman KA; Bazinet A; Pertl K; Luoma JB; des Jarlais D; Bielavitz S; Korthuis PT (The International journal on drug policy, 2025)

Psychedelic Drug Checking: Analytical and Strategic Challenges in Harm Reduction for Classic Psychedelics. - Hirschfeld T; Blei F; Stegemann L; van der Gouwe D; Smit-Rigter L. (2025)

Psilocybin Outside the Clinic: Public Health Challenges of Increasing Publicity, Accessibility, and Use. - Hutchison KE; Hooper JF; Karoly HC. (2025)

Perceptions of Psilocybin-Assisted Psychotherapy and Standard Interventions for Nicotine Cessation. - Kamilar-Britt P; Oliva AB; Earleywine M. (2025)

The Effect of Magic Mushroom (Psilocybe azurescens) on Social Interaction, Anxiety- and Depressive-Like Behaviors in Male Rats; the Role of Neuroinflammation, Oxidative Stress, and Neurotrophic Factors. - Moghadam H; Akbari P; Beirami E; Nabavifard S; Ameli A; Valian N. (2025)

Pharmacological Management of Anxiety in End-of-Life Care: A Systematic Review of Benzodiazepines, Opioids, and Psilocybin. - Freitas da Costa B; Hartmann P; Pagnin D. (2025)

Magic mushrooms and mood: Exploring psilocybin as a depression treatment. - Rasool M; Hannan TM; Imam M. (2025)

Psychedelic-Related Psychosis: From Model Psychosis to Psychotherapy. - Bröcker AL; Majić T; Montag C. (2025)

Classifying Psychedelic-Related Complications. - Majić T; Gouzoulis-Mayfrank E; Evens R. (2025)

New Antidepressant Development in the Treatment of Depression. - Spiti A; Caldirola D; Perna G. (2025)

Psychedelics: Future Therapeutics in Major Depression? - Olivier B; Olivier JDA. (2025)

Rural-Urban Disparities in Access to Interventional Psychiatry Treatments among VA Patients. - Shiner B; DuFort V; Peltzman T; Watts BV. (2025)

Neuroscience: What doesn't kill you makes you stronger. - Kucukdereli H; Douglass AM. (2025)

From trials to clinics: investigators' perspectives on translating psychedelic research into clinical care. - Mitchell J; Neitzke-Spruill L; Mathai DS; Robinson JO; Kavan Z; Averil LA; McGuire AL. (2025)

[Clinical application and mechanistic studies of psychedelics for treatment of depression: progress and future challenges]. - Xia K; Gao T. (2025)

Psychedelic therapy and postpartum depression: priorities and prospects. - Thuery G; Crossen F; Mc Loone D; Hinds C; Duffy R; Jairaj C; Harkin A; Kelly JR (Therapeutic advances in psychopharmacology, 2025)

Editorial: Psychedelic-assisted psychotherapies: from clinical trials to credibility. - Evans M; Charrette A (Frontiers in neuroscience, 2025)

Correction: Characteristics and mental health of psychedelic mushroom and multi-psychedelic users relative to non-psychedelic users in American adults, 2020-2021. - Abramsky-Sze S; Marseille E; Matzopoulos R; Morlock R; Lerer L (Frontiers in psychiatry, 2025)

The effects of psilocybin on time perception in humans: A comparative analysis of subjective and objective measures. - Scholle P; Wenke Š; Nekovářová T; Zaytseva Y; Tylš F; Brunovský M; Horáček J; Andrashko V; Koudelka V; Viktorinová M; Viktorin V; Hájková K; et al. (2025)

Thirty Years of Ibogaine Research: A Literature Review on Clinical Perspectives. - Kervadec E; Bezo A; Serreau R; Strika-Bruneau L; Fauvel B; Amirouche A; Benyamina A; Romeo B (Journal of clinical psychopharmacology, 2025)

Self-Transcendent Perceptual Dynamics and the Effects of Dispositional Mindfulness on Altered States of Consciousness: A Prospective Longitudinal Observational Study of a Naturalistic Psychedelic Retreat - Ehmann S; Mosahvili N; White A; Cuzzupe J; Tompkins B; McKibben J; Allen JJ; Gawrysiak M. (PsyArXiv, 2025)

Self-Transcendent Perceptual Dynamics and the Effects of Dispositional Mindfulness on Altered States of Consciousness: A Prospective Longitudinal Observational Study of a Naturalistic Psychedelic Retreat (PsyArXiv, 2025)

Psilocybin: clinical potential, mechanistic insights, and biotechnological advances for scalable production. - Islas-Vargas J; Armenta S; Rivera-Román ÁA; Hernández-León S; Méndez-Hernández JE; Arce-Cervantes O. (2025)

The helioscope effect: A new framework for evaluating trauma-related memory processing in psychedelic experiences. - Diehl VJ; Calder AE; Hasler G. (2025)

A Randomized Double-blinded Controlled Trial for the Treatment of Persisting Symptoms After Concussion With Psilocybin-assisted Therapy: A Safety and Feasibility Trial - University of Calgary (ClinicalTrials.gov, 2025)

Microdosing Psychedelics to Improve Mood - Rotem Petranker (ClinicalTrials.gov, 2025)

Distinguishing 4- vs 5-Hydroxy-N,N-Dimethyltryptamine (Psilocin vs Bufotenine) Using Hydrogen-Deuterium Back-Exchange. - Christopher MW; Prentice BM; Garrett TJ. (2025)